Observation and extirpation of a giant-size type-B2 thymoma IIb with its histological, macroscopic, and computer tomogram correlate, and literature review
Maximilian de Bucourt, Marc Swierzy, Anja Dankof, Ulf Teichgräber,
Jens-Carsten Rückert
Charité, University Medicine Berlin, Germany
Correspondence: Maximilian de Bucourt, Charité, University Medicine Berlin, Department of Radiology, Charité Platz 1, 10117 Berlin, Germany. E-mail: mdb@charite.de
Key words: thymoma.
Conflict of interest: the authors report no conflicts of interest.
Received for publication: 19 March 2010.
Revision received: 20 April 2010.
Accepted for publication: 23 April 2010.
©Copyright M. de Bucourt et al., 2010
Licensee PAGEPress, Italy
Rare Tumors 2010; 2:e30
doi:10.4081/rt.2010.e30
AbstractThis report describes the interdisciplinary approach and solving algorithm of a DIN 9001:2000 certified tumor board in managing a giant-size type-B2 thymoma IIb in an elderly patient. The process of managing the thymoma with specialists of surgery, internal medicine, radiology, and pathology until finally extirpation and continuous follow-up is described. Respective computerized tomography scans, histology, macro-pathology, and operative pictures of the case are provided as well as an up-to-date literature review.
|
Introduction
We report an extirpation of a giant-size type-B2-thymoma IIb, according to the modified clinical Masaoka et al.1,2 and histological WHO3,4 stages. Previously a period of controlled observation by an interdisciplinary and DIN 9001:2000 certified tumor conference team was pursued. Our case report is supported by histological, macroscopic, and computerized tomography (CT) pictures.
Case Report
An 82-year-old woman presented with a cough enduring for weeks and a feeling of thoracic pressure. Anamnestically the patient had no history of severe thoracic illness. On clinical admission, routinely collected laboratory values – including leukocytes – were normal. A chest CT scan with intravenous contrast was performed and depicted a solid tumor of about 10¥5¥6 cm in the superior anterior mediastinum. The tumor was located in the immediate vicinity of the pericardium above the aortic arch and superior vena cava, with no signs of infiltrative growth. CT-acquired histology via Biopince (Amgiotech, Medical Device Technologies Inc., Florida, USA; 10 cm, 18ga) revealed a thymoma as the diagnosis. The post-diagnosis algorithm for adequate treatment of the patient included an interdisciplinary and DIN 9001:2000 certified tumor conference with specialists of surgery, internal medicine, radiology, and pathology. Because the patient’s symptoms were ameliorated, and especially given her age, it was decided first to pursue a wait-and-see strategy. Half a year later the patient presented again. A new CT scan revealed an increase in the size of the thymoma to 10¥6¥10 cm. The continuous growth increasingly affected cardiovascular structures in the mediastinum (Figure 1). The trachea was not deviated and the underlying diaphragm did not appear paralytic. It was decided to extirpate the tumor surgically, taking into account the increased risk of surgical interventions, especially in elderly patients.
The surgical procedure lasted for about 150 min. It included a complete sternotomy and mobilization of the tumor per continuitatem from caudal to cranial, and finally extirpation (Figure 2). Grossly, the tumor was adherent to the mediastinal pleura and pericardium without invading these structures. It was fed partly by one branch of the right internal thoracic artery – visible in the CT scan – that had to be occluded surgically. One Redon drain (10 Ch.) was placed dorsal to the sternum and one pleural drain (24 Ch.) was placed on each side as well.
Macroscopically, the biggest part of the delicately encapsulated, knotty, and mainly solid tumor measured 75¥70¥55 mm. For histo- and macro-pathological post-processing, the thymoma was cut into slices (Figure 3). In general, the cutting area depicted was of a homogenous, brown appearance, with some focal cystic and some hemorrhagic lesions of a maximum of 15 mm. Adjacent extirpated soft tissue measured 120¥75¥20 mm. Microscopically, the tumor presented a lobular architecture. Multiple polygonal cells with large nuclei and prominent nucleoli could be identified (Figure 4A). Immunohistochemically, a Pan-CK and CK19 expression could be identified (Figure 4B) as well as a concomitant infiltrate of partly CD3-positive lymphocytes (Figure 4C). The lymphocytological proliferation rate MIB1 averaged 80% (Figure 4D).
In the final pathological classification, the tumor was staged type-B2 thymoma IIb according to the modified clinical Masaoka1,2 and histological WHO3,4 stages. As expected, CRP rose post-intervention to a maximum of 11.54 mg/dL (<0.5) on day 4 and decreased thereafter, to 6.67 mg/dL on day 5. The postoperative course was ceteris paribus uneventful. The patient was discharged on postoperative day 6. Follow-up studies up to this date have not revealed any recurrence of the tumor and will be continued.
| Figure 1. Intravenous chest CT scan. (A) Axial view. Note the vicinity of the tumor (*) to the internal thoracic artery (arrow). (B) Sagittal view. Note the delicate location of the tumor (*) above the right atrium (#). (C) Coronal view. Note the vicinity of the tumor (*) to the mediastinal cardiovascular structures such as the ascending aorta and aortic arch (+), right atrium (#) and left brachiocephalic vein (~). |
| Figure 2. Intraoperative photograph of the recently extirpated thymoma. |
| Figure 3. Cross-section preparation photograph of the macro-pathological, post-processed, delicately capsulated, knotty, and mainly solid thymoma. |
 |
Figure 4. (A) Neoplastic epithelial cells of the thymoma in a lymphocytic background (Giemsa stain; 200x magnification). (B) Immunohistochemical expression of cytokeratin 19 highlights the neoplastic epithelial component (CK19; 100x magnification). (C) Perivascular accumulation of mature CD3-positive T-lymphocytes (CD3; 100x magnification). (D) High proliferative activity, sparing areas of accumulated mature T-lymphocytes (MIB1; 50x magnification). |
Discussion
Thymomas have a prevalence of 0.1-0.4/100,000.5 They account for about 0.2-1.5% of all malignant tumors and for about 50% of all tumors in the upper ventral mediastinum; distribution between sexes is about equal, and the majority of patients are aged between 40 and 60 years.6 Thymomas are epithelial tumors generally considered to have an indolent and slow growth pattern, but should be regarded as malignant nonetheless because of the potential for local invasion and, less often, systemic metastases.
One third of thymomas is detected casually in body imaging, one third of patients presents with local symptoms, and one third is diagnosed within myasthenia gravis evaluation.6 The latter seems especially noteworthy as other paraneoplastic autoimmune diseases occur only occasionally; for example, with small cell lung cancers or gynecological tumors, whereas myasthenia gravis is associated with thymomas in at least 30% of patients.7 Ectopic cervical thymomas are a rare and diagnostically challenging entity that frequently is misdiagnosed on fine needle aspiration cytology and frozen sections.8
The most commonly used classification of thymomas was initially introduced by Masaoka et al.1 in 1981, and describes four stages of thymoma with special reference to the clinical stage. The most recent modifications were published in 20033 and included more histological data. Generally, recurrences after complete surgical resection are rare but have been described in the literature.9,10,11 Spontaneous tumor regression of invasive thymoma12 as well as of thymoma-associated immunodeficiency have been described as well.13
The effect of radiation therapy is discussed controversially. It is generally agreed that patients with a Masaoka III stage and higher benefit from radiation therapy. Chen et al. state that adjuvant radiotherapy after complete tumor resection for patients with stage II thymoma neither reduced recurrence rates significantly, nor improved survival rates.14 Several prognostic factors for thymic tumors, including the Masaoka stage, WHO histology, complete resection, great vessel invasion, and size of thymoma have been identified.15 In a recent publication, Wright et al. demonstrated that thymoma size is an independent risk factor and tumors measuring >8 cm were found to be recurrent in 29%,16 further justifying continuous follow-up studies of the patient presented. Tumor size of >11 cm as well as the histological type-B3 thymoma14 have also been described as significant independent prognostic variables.17 Concerning prognostic indicators after surgery for thymoma, Okereke et al. recently stated that long-term disease-specific survival can be expected not only after surgery for early-stage thymoma but also after surgery for advanced disease, including patients with pleural metastases but limited, however, by patients who undergo surgery for stage IV-A disease, who do have reduced disease-free survival.18 If the tumor is indeed malignant, the risk of lymph node metastasis generally is estimated to be 1.8% and does not seem to impact on overall survival rate.19
Twenty-year survival rates of type II thymomas, according to the Masaoka staging system, are reported to be 91%.20 Thymomas of the presented giant size are extremely rare. It is noteworthy that the delicate size and location of the tumor and the age of our patient necessitated deliberate surgical intervention.
References
1. Masaoka A, Mondem Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stage. Cancer 1981;48:2485-92.[PubMed]
2. Weydert JA, De Young BR, Leslie KO. Recommendations for the reporting of surgically resected thymic epithelial tumors. Hum Pathol 2009;40:918-23.[PubMed]
3. Rosai J. Histological typing of tumors of the thymus. World Health Organization International Histological Classification of Tumors. 2nd ed. New York, Berlin: Springer, 1999.
4. Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma: a clinicopathologic study based on the new World Health Organization classification. J Thor Cardiovasc Surg 2003;126:1134-40.[PubMed]
5. Kahraman A, Miller M, Maldonado-Lopez E, et al. A 55-year-old woman with thymoma and hypogammaglobulinemia (Good syndrome), ulcerative colitis, and cytomegalovirus infection. Med Klin (Munich) 2009;104:150-4. [PubMed]
6. Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol 2005;17:140-6.[PubMed]
7. Marx A, Willcox N, Leite MI, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010, Apr 12. Epub ahead of print [PubMed]
8. Yan B, Lim D, Petersson F. Ectopic Cervical Thymoma: A Report of Two Cases of a Rare Entity Frequently Misdiagnosed on Fine Needle Aspiration Cytology and Frozen Section. Head Neck Pathol 2010, Mar 2010. Epub ahead of print [PubMed]
9. Fechner RE. Recurrence of noninvasive thymomas. Cancer 1969;23:1423-7.[PubMed]
10. Kirschner PA. Reoperation for thymoma: report of 23 cases. Ann Thorac Surg 1990; 49:550-5.[PubMed]
11. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 1996; 112:376-84.[PubMed]
12. Yutaka Y, Omasa M, Shikuma K, et al. Spontaneous regression of an invasive thymoma. Gen Thorac Cardiovasc Surg 2010;58:212-3. [PubMed]
13. Vitiello L, Masci AM, Montella L, et al. Thymoma-associated immunodeficiency: a syndrome characterized by severe alterations in NK, T- and B-cells and progressive increase in naïve CD8+ T-cells. Int J Immunopathol Pharmacol 2010;23:307-16. [PubMed]
14. Chen YD, Feng QF, Lu HZ, et al. Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys 2010, Apr 6. Epub ahead of print[PubMed]
15. Wright CD, Kessler KA. Surgical treatment of thymic tumors. Semin Thorac Cardiovasc Surg 2005;17:20-6.[PubMed]
16. Wright CD, Wain J, Wong DR, et al. Predictors of recurrence in thymic tumors: importance of invasion, WHO histology, and size. J Thorac Cardiovasc Surg 2005; 130:1413-21.[PubMed]
17. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 1995;60:908-14.[PubMed]
18. Okereke IC, Kesler KA, Morad MH, et al. Prognostic indicators after surgery for thymoma. Ann Thorac Surg 2010;89:1071-9. [PubMed]
19. Kondo K, Monden Y. Lymphogenous and hematogenous metastasis of thymic epithelial tumors. Ann Thorac Surg 2003; 76:1859-5.[PubMed]
20. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behaviour of thymoma: a clinical study of 273 patients. Cancer 2002;94:624-32.[PubMed]
[TOP]
This work is licensed under a Creative Commons Attribution 3.0 License.
Rare Tumors [ISSN 2036-3605, eISSN 2036-3613] is an Open Access, peer-reviewed journal published by PAGEPress, Pavia, Italy. All credits and honors to PKP for their OJS.